Whales with a lot of money to spend have taken a noticeably bullish stance on Viking Therapeutics.
Looking at options history for Viking Therapeutics VKTX we detected 15 trades.
If we consider the specifics of each trade, it is accurate to state that 73% of the investors opened trades with bullish expectations and 6% with bearish.
From the overall spotted trades, 2 are puts, for a total amount of $82,350 and 13, calls, for a total amount of $631,622.
Projected Price Targets
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $20.0 to $120.0 for Viking Therapeutics over the recent three months.
Volume & Open Interest Development
In terms of liquidity and interest, the mean open interest for Viking Therapeutics options trades today is 989.58 with a total volume of 698.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Viking Therapeutics's big money trades within a strike price range of $20.0 to $120.0 over the last 30 days.
Viking Therapeutics Call and Put Volume: 30-Day Overview
Largest Options Trades Observed:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| VKTX | CALL | TRADE | BULLISH | 06/21/24 | $10.7 | $9.4 | $10.2 | $75.00 | $81.6K | 2.3K | 83 |
| VKTX | CALL | TRADE | NEUTRAL | 06/21/24 | $17.3 | $14.9 | $16.02 | $65.00 | $70.4K | 363 | 0 |
| VKTX | CALL | TRADE | BULLISH | 01/16/26 | $54.0 | $52.4 | $54.0 | $30.00 | $64.8K | 347 | 0 |
| VKTX | CALL | SWEEP | BEARISH | 06/21/24 | $7.6 | $7.0 | $7.0 | $85.00 | $63.0K | 545 | 91 |
| VKTX | CALL | TRADE | BULLISH | 05/17/24 | $12.4 | $11.2 | $12.4 | $65.00 | $55.8K | 2.7K | 0 |
About Viking Therapeutics
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Current Position of Viking Therapeutics
- With a volume of 712,447, the price of VKTX is up 0.74% at $75.97.
- RSI indicators hint that the underlying stock may be approaching overbought.
- Next earnings are expected to be released in 85 days.
Professional Analyst Ratings for Viking Therapeutics
Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $90.0.
- In a cautious move, an analyst from HC Wainwright & Co. downgraded its rating to Buy, setting a price target of $90.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Viking Therapeutics options trades with real-time alerts from Benzinga Pro.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
